







an Open Access Journal by MDPI

Recent Advances in Colorectal Cancer Diagnostics and Treatments

Guest Editors:

Prof. Dr. Luis Buianda

Prof. Dr. Ajay Goel

Dr. Ane Etxart

Deadline for manuscript submissions:

closed (10 June 2022)

Message from the Guest Editors

Dear Colleagues,

Colorectal cancer is the most common tumor in Western countries when men and women are considered together, and the second in mortality after lung cancer with a survival of 60–70% at 5 years. The objective of all of us who work in and research this disease would be to develop strategies so that in the coming years we can reach 80-90% survival at 5 years. For this, it is necessary to carry out disease prevention policies, develop research that improves biomarkers to detect colon cancer in early stages, extend screening programs, detect people at high risk of developing colon cancer through genetic studies and molecular studies, improve and standardize diagnostic and prognostic techniques, develop methods for detecting recurrences and complete responses (e.g., in rectal cancer), improve treatments in the advanced stages. and develop personalized treatments. For all the above, this Special Issue aims to collect outstanding research in any of these fields that will help us to achieve our objectives.

Prof. Dr. Luis Bujanda

Prof. Dr. Ajay Goel Dr. Ane Etxart













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us